Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 14/20 | 0.75 |
| ▸ | LMNA | P02545 | 6/20 | 0.74 |
| ▸ | MAPT | P10636 | 6/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.74 |
| ▸ | USP2 | O75604 | 4/20 | 0.74 |
| ▸ | TP53 | P04637 | 3/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.74 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.74 |
| ▸ | HTR1A | P08908 | 2/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.74 |
| ▸ | DRD2 | P14416 | 2/20 | 0.74 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.74 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.74 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flupimazine SCHEMBL11684459 | 0.99 | LMNA (0.74) | FPR2LMNAMAPTCYP3A4MAPK1 | |
| SCHEMBL11686356 | 0.95 | FPR2 (0.73) | FPR2LMNAMAPTCYP3A4MAPK1 | |
| Hydrochloric Acid SCHEMBL11686460 | 0.94 | LMNA (0.72) | FPR2LMNAMAPTCYP3A4MAPK1 | |
| SCHEMBL11686604 | 0.88 | KDM1A (0.64) | FPR2LMNAMAPTCYP3A4MAPK1 | |
| Hydrochloric Acid SCHEMBL11688573 | 0.87 | KDM1A (0.62) | FPR2LMNAMAPTCYP3A4MAPK1 | |
| SCHEMBL11689858 | 0.87 | FPR2 (0.66) | FPR2LMNAMAPTCYP3A4MAPK1 | |
| SCHEMBL11690617 | 0.87 | FPR2 (0.66) | FPR2LMNAMAPTCYP3A4MAPK1 | |
| SCHEMBL11685591 | 0.87 | FPR2 (0.67) | FPR2LMNAMAPTCYP3A4MAPK1 | |
| SCHEMBL10168352 | 0.87 | FPR2 (0.98) | FPR2LMNAMAPTCYP3A4MAPK1 | |
| SCHEMBL11686351 | 0.86 | FPR2 (0.70) | FPR2LMNAMAPTCYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-4018922-A | NEUROLEPTICS, ANALGESICS, SPASMOLYTICS, AND ANTIHISTAMINES | ROUSSEL-UCLAF (FR) | 1977-04-19 | — | — | US | claimed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-9494572-B2 | Method and compositions for treating cancer and related methods | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2016-11-15 | — | — | US | disclosed |
| US-9134297-B2 | Method and compositions for treating cancer and related methods | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150224101-A1 | Method and Compositions for Treating Cancer and Related Methods | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2015-08-13 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| US-4018922-A | NEUROLEPTICS, ANALGESICS, SPASMOLYTICS, AND ANTIHISTAMINES | ROUSSEL-UCLAF (FR) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | FPR2 1052/4885LMNA 1552/4885MAPT 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.